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Abstract
Antibodies against cyclic citrullinated peptide (CCP) and 
rheumatoid factors (RFs) have been demonstrated to predate 
the onset of rheumatoid arthritis (RA) by years. A nested case- 
control study was performed within the Northern Sweden 
Health and Disease study cohort to analyse the presence of 
shared epitope (SE) genes, defined as HLA-DRB 1*0404 or 
DRB1*0401, and of anti-CCP antibodies and RFs in individuals 
who subsequently developed RA. Patients with RA were 
identified from among blood donors whose samples had been 
collected years before the onset of symptoms. Controls 
matched for age, sex, and date of sampling were selected 
randomly from the same cohort. The SE genes were identified 
by polymerase chain reaction sequence-specific primers. Anti- 
CCP2 antibodies and RFs were determined using enzyme 
immunoassays. Fifty-nine individuals with RA were identified as 
blood donors, with a median antedating time of 2.0 years
(interquartile range 0.9-3.9 years) before presenting with 
symptoms of RA. The sensitivity for SE as a diagnostic indicator 
for RA was 60% and the specificity was 64%. The 
corresponding figures for anti-CCP antibodies were 37% and 
98%, and for RFs, 1 7 -42%  and 94%, respectively. In a logistic 
regression analysis, SE (odds ratio [OR] =  2.35), anti-CCP 
antibodies (OR =  15.9), and IgA-RF (OR =  6.8) significantly 
predicted RA. In a combination model analysis, anti-CCP 
antibodies combined with SE had the highest OR (66.8, 95% 
confidence interval 8.3-539.4) in predicting RA, compared with 
anti-CCP antibodies without SE (OR =  25.01, 95% confidence 
interval 2.8-222.2) or SE without anti-CCP antibodies (OR =  
1.9, 95% confidence interval 0.9-4.2). This study showed that 
the presence of anti-CCP antibodies together with SE gene 
carriage is associated with a very high relative risk for future 
development of RA.
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Introduction
Autoimmune diseases, such as rheumatoid arthritis (RA), 
are believed to develop as a result of dysregulation of the 
immune system, leading ultimately, in RA, to the clinical fea­
tures of inflammation and destruction in several jo ints [1]. 
The aetiology of RA has been suggested to be an interac­
tion between genetic and environmental factors. To date, it 
has not been possible to identify individuals at early stages 
of this dysregulation, i.e. before presentation with clinically
obvious polyarthritis. If methods were available to predict 
future development of RA, a better understanding of the 
events triggering the disease would be achieved, thereby 
creating the possibility of developing and testing preventive 
measures and of instituting therapy at earlier stages of d is­
ease development than is current practice.
Previous studies have demonstrated that the presence of 
rheumatoid factors (RFs) of IgM, IgG, and IgA class [2,3]
CCP =  cyclic citrullinated peptide; CI =  confidence interval; IQR =  interquartile range; NSHDS =  Northern Sweden Health and Disease Study; OR 
=  odds ratio; RA =  rheumatoid arthritis; RF =  rheumatoid factor; SD =  standard deviation; SE =  shared epitope. R303
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predict the development of rheumatoid arthritis and in a 
case-contro l study we found that antibodies against cyclic 
citrullinated peptide (CCP), as well as RFs, predated the 
onset of RA by several years [3]. Both anti-CCP antibodies 
and IgA-RF predicted the development of RA, w ith the 
highest predictive value for anti-CCP antibodies, indicating 
that citrullination and production of anti-CCP antibodies 
and RF are early processes in the development of RA [3]. 
The HLA-DRB1 locus has been shown to be linked to and 
associated w ith RA, w ith an especially high risk in individu­
als w ith compound heterozygosity for shared epitope (SE) 
genes [4]. However, there are no previous reports of stud­
ies combining serological and genetic factors in order to 
optimise the prediction of a future risk of developing RA. In 
the present study, we have evaluated the significance of 
the presence of SE genes, defined as D R B1*0404 or 
D R B 1*0401 , in relation to anti-CCP antibodies and RFs in 
individuals who subsequently developed RA.
Materials and methods
Subjects
A nested case-contro l study was performed w ithin the 
Northern Sweden Health and Disease Study (NSHDS) and 
the Maternity cohort of Northern Sweden. All adult individ­
uals of the county of Västerbotten were invited to partici­
pate; consequently, the cohorts are population-based and 
no individual was excluded. The NDHDS cohort consists of 
three subcohorts, which, together w ith conditions for 
recruitment into the cohorts and the collection and storage 
of blood samples, have previously been described in detail 
[3]. The registry of patients who fulfilled the American C o l­
lege of Rheumatology classification criteria for RA [1] and 
who attended the Department of Rheumatology, University 
Hospital, Umeà (the only medical centre for rheumatology 
in the county of Västerbotten), and with a known date of 
onset of symptoms or signs of jo int disease, was coana­
lysed w ith the registers of the cohorts from the Blood Bank 
for Västerbotten located in Umeà. At the time of the study, 
the median duration of disease since the diagnosis of RA 
was 3.0 years (interquartile range [IQR] 1 .8 -5 .8  years). 
Eighty-six individuals were identified from the cohorts as 
having donated blood samples before the onset of symp­
toms or signs of jo int disease. Samples from three individ­
uals were not available. O f the remaining 83  individuals 
(referred to here as 'prepatients'), blood samples for DNA 
analysis were available only from the NSHDS cohort, result­
ing in 59 prepatients (45 women and 14 men); the Mater­
nity cohort did not include collection of samples for DNA 
analysis. Power calculations showed that two controls per 
patient w ould be sufficient, based on pretest probability of 
our previous results of HLA-DR4 frequencies in patients 
and controls from this area [5]. Therefore, we selected for 
genetic analysis two controls (out of the four who were pre­
viously analysed for antibody titres [3]) for every prepatient. 
The controls were randomly selected from the same subco­
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horts as the original cases w ithin the NSHDS cohort and 
matched for sex, for age at the time of blood sampling, and 
for area of residence (rural or urban). The mean age of the 
prepatients at the time of blood sampling was 53 years 
(range 3 1 -6 7  years) and of the controls, 53 years (range 
3 0 -6 7  years). The median sampling time before onset of 
symptoms of jo int disease was 2.0 years (IQR 0 .9 -3 .9  
years). The antedating time for the samples was calculated 
to the onset of any symptoms of RA in all prepatients. Add i­
tional samples were collected from the prepatients at their 
first visit to the early-arthritis clinic (n =  52), i.e. when RA 
was diagnosed. On average, the diagnosis of RA was 
established 7.1 ±  2.8 (SD) months after the first symptoms 
of jo int disease. The mean age at the onset of disease was 
56.6 years, range 3 4 -6 8  years. The Ethics Committee 
approved this study at the University Hospital, Umeà, and 
the blood donors to the Blood Bank had given their written 
informed consent.
HLA-DRB1 genotyping was performed using polymerase 
chain reaction sequence-specific primers from DR low-res- 
olution kit and DRB1*04 subtyping kit (Olerup SSP AB, 
Saltsjöbaden, Sweden). The SE genes were defined as 
D R B1*0404 and D R B1*0401. Samples for DNA analysis 
from one prepatient and three controls were not available, 
and HLA typing of one prepatient and tw o controls was 
unsuccessful. Consequently, results of HLA typing were 
available from 57 prepatients and 112 controls.
The anti-CCP2 (Mark2) antibodies and the RFs were deter­
mined using enzyme-linked immunoassays as previously 
described [3].
Statistical analysis
The chi-square test was used for testing differences in fre­
quencies of categorical data between groups. The sensitiv­
ity and specificity of SE gene carriage both separately and 
in combination w ith anti-CCP antibodies and RFs were cal­
culated. Logistic regression analyses were used to esti­
mate the odds ratio (OR) for the presence of SE gene 
carriage separately and in combination w ith anti-CCP anti­
bodies or RFs as predictors for RA. The OR was calculated 
with 95%  confidence intervals (CI). All P  values are tw o ­
sided, and P  values equal to or less than 0.05 were consid­
ered statistically significant. The calculations were per­
formed using the SPSS package for W indow s (version 
11.0; SPSS, Chicago, IL, USA).
Results
The sensitivity found for the presence of SE genes as a 
diagnostic indicator for RA in prepatients was 60%  (34/57) 
and the specificity was 64%  (Table 1). The respective fig ­
ures for carriers of two SE genes were 28%  (16/57) and 
95% . The specificity for the allele B1*0401 (74%) was 
higher than that for SE given either B1*0401 or B 1*0404
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Table  1
S e n s itiv ity  and s p e c ific ity  as d ia g n os tic  in d ica to rs  fo r  
rheum ato id  a rth r it is  fo r  a n tib o d ie s  aga ins t cyc lic  c itru llin a te d  
pep tide  (anti-C C P A b) and fo r  rheum a to id  fa c to r (RF) o f IgA, 
IgM , and IgG iso types, in co m b in a tio n  w ith  the  presence o f a 
shared e p ito pe  (SE) a lle le  -  HLA-DRB1*0401 o r B1*0404 -  in 59 
’p re p a tie n ts ’ w hose  b lood  sam p les an teda ted  th e  appearance 
o f sym ptom s o f rheum a to id  a rth r it is  (m ed ian  2.0 years 
[in te rq u a rtile  range 0 .9 -3 .9 ]) and in  118 m atched con tro ls .
Variables Sensitivity Specificity
% 95%CI % 95%CI
Anti-CCP Ab 37 25-51 98 93 -100
IgA-RF 42 29-56 94 8 7 -9 8
IgM-RF 22 12-35 94 8 7 -9 8
IgG-RF 17 8 -3 0 94 8 7 -9 8
SE (B1*0404 or 0401)1 60 45-72 64 5 4 -7 3
SE + anti-CCP Ab 28 17-42 99 94 -100
SE + IgA-RF 25 14-38 98 93 -100
SE + IgM-RF 14 6 -2 7 98 93 -100
SE + IgG-RF 11 4 -2 2 99 94 -100
SESE (B1*0404 or 0401)1 28 17-42 95 8 8 -9 8
SESE + anti-CCP Ab 14 6 -2 7 99 94 -100
SESE + IgA-RF 7 2 -1 8 99 94 -100
SESE + IgM-RF 5 1 -1 6 99 94 -100
SESE + IgG-RF 4 0 -1 4 100 95 -100
1Analysed in 57 prepatients and in 112 controls. CI, confidence 
interval.
(data not shown). The frequencies of the presence of one 
or both of the SE genes studied in the prepatients were sig­
nificantly greater than in the controls (P =  0 .003 and P  =  
0.0001, respectively). O f the prepatients, 37%  (22/59) 
tested positive for anti-CCP-antibodies, with a specificity of 
98% . The sensitivity for IgA-RF was 42%  (25/59), for IgM- 
RF 22%  (13/59), and for IgG-RF 17%  (10/59) (Table 1). 
The specificity was 94%  for all three RF isotypes. The com ­
bination of SE gene carriage and anti-CCP antibodies 
increased the specificity to 99% , as did the combination of 
SE genes and IgG-RF (Table 1). The presence of double 
doses of the SE genes studied, in combination w ith either 
anti-CCP-antibodies, IgA-RF, or IgM-RF, gave a specificity 
of 99% , and, in combination w ith IgG-RF, of 100%  (Table 
1).
In a univariate logistic regression model, SE gene carriage, 
and particularly carriage of two SE alleles, significantly pre­
dicted RA (OR =  2.66, 95% C I 1 .3 8 -5 .1 2  and OR =  6.89, 
95% C I 2 .5 2 -1 8 .8 4 , respectively). In multivariate models 
including anti-CCP antibodies and RFs of all isotypes, sin­
gle or double SE gene carriage significantly predicted RA 
in addition to our previously described predictive value of
anti-CCP antibodies and IgA-RF [3]. The OR for SE gene 
carriage was 2.35 (95% CI 1 .05 -5 .26 ) and for double SE 
gene carriage 7.31 (95% CI 2 .2 6 -2 3 .6 7 ) (data not shown).
In a univariate logistic regression analysis, the combination 
of anti-CCP antibodies and SE gene carriage gave an OR 
of 66.8, while the presence of anti-CCP-antibodies alone 
gave an OR of 25.1 for the risk of developing RA compared 
with not having any of these factors (Table 2). The calcula­
tion on the SE allele B1*0401 selectively in the same model 
gave essentially the same results (data not shown). Further­
more, in the same type of analysis, SE gene carriage and 
IgA-RF showed similar results but at a lower level (Table 2). 
However, in the analysis including IgM-RF and SE, only SE 
gene carriage separately or in combination w ith IgM-RF sig­
nificantly predicted RA; the same pattern was found for 
combinations of IgG-RF and SE (Table 2 ).
Except for a borderline significant association between the 
SE allele B1*0401 and anti-CCP-antibodies (P =  0.051), 
no significant association between SE gene carriage and 
the expression of anti-CCP-antibodies or RFs could be 
demonstrated (data not shown). As previously reported [3], 
anti-CCP antibodies and RFs were associated (data not 
shown).
W hen the prepatients were diagnosed after having devel­
oped RA, the sensitivity for anti-CCP antibodies was 71%, 
for IgG-RF 45% , for IgM-RF 73% , and for IgA-RF 71%. As 
regards SE, a significant association was found only 
between the presence of anti-CCP antibodies and 
B1*0401 (P =  0.027), and not between SE and any of the 
RFs.
Discussion
This study shows a greatly increased OR for the develop­
ment of RA in individuals w ith the combination of SE gene 
carriage and anti-CCP antibodies or an RF of any isotype, 
in comparison w ith individuals not having any of the factors 
or having any one of them separately. In particular, the com ­
bination of SE gene carriage and the presence of anti-CCP 
antibodies appeared to be prognostic for the future 
development of RA. Previous studies by us [3] and others 
[2] have demonstrated that an increased production of 
autoantibodies may precede the development of RA. H ow ­
ever, this is the first report in which autoantibody analyses 
have been combined w ith genotyping to show a remarkably 
high predictive value for the future development of RA. The 
main methodological strength of the current study is that 
the blood sampling of individuals who later developed RA 
and their controls was population based.
The results do not support the notion that there is a direct 
association between SE gene carriage and the occurrence 
of antibodies directed to C C P (or RFs) leading to the devel-
R305
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Table  2
R esults o f lo g is tic  regress ion  analyses o f anti-CC P a n tib od ie s  (anti-C C P A b ) o r rheum a to id  fa c to r (RF) o f IgG, IgM , o r IgA  iso type  
and shared e p ito pe  (SE) in p red ic ting  rheum a to id  a rth r it is , analysed in in d iv id u a ls  w ho  la te r deve loped th e  d isease  and in con tro ls .
Combinations of variables Patients (no.) Controls (no.) OR 95%CI
SE" and anti-CCP Ab' 17 71 1.0
SE+ and anti-CCP Ab- 18 39 1.9 0.9-4.2
SE’ and anti-CCP Ab+ 6 1 25.1 2.8-222.2
SE+ and anti-CCP Ab+ 16 1 66.8 8.3-539.4
SE- and IgA-RF- 12 67 1.0
SE+ and IgA-RF- 20 38 2.9 1.3-6.7
SE- and IgA-RF+ 11 5 12.3 3.6-41.7
SE+ and IgA-RF+ 14 2 39.2 7.9-193.9
SE- and IgM-RF" 18 71 1.0
SE+ and IgM-RF" 26 38 2.6 1.2-5.2
SE- and IgM-RF+ 5 5 3.7 0.99-14.3
SE+ and IgM-RF+ 8 2 14.9 2.9-76.3
SE- and IgG-RF" 19 67 1.0
SE+ and IgG-RF 28 39 2.5 1.3-5.1
SE- and IgG-RF+ 4 5 2.8 0.7-11.6
SE+ and IgG-RF+ 6 1 21.2 2.4-186.5
CI, confidence interval; OR odds ratio.
opment of RA, but rather suggest that there is a synergistic 
interaction between these factors. Our knowledge about 
what triggers the production of anti-CCP antibodies in 
healthy individuals is limited, as is the role of SE genes in 
this context. The conversion of arginine to citrulline in HLA- 
DRB1*0401 transgenic mice has been demonstrated to 
significantly increase activation of CD4+ T cells [6]. In a pre­
vious study of patients with early RA, a significant associa­
tion between anti-CCP antibodies and expression of 
B1 *0401 /0101  was reported [7]. This finding suggests 
that individuals carrying the SE genes may have more sus­
tained T- and B-cell responses to citrullinated antigens than 
noncarriers. Taken together, these data suggest that in indi­
viduals carrying one or tw o SE genes, a specific T-cell- 
dependent immune response to citrullinated peptides may 
contribute to the occurrence of RA. In the prepatient 
cohort, there appeared to be a weak association, w ith bor­
derline statistical significance, between the presence of 
anti-CCP antibodies and B1*0401. This association was 
strengthened when the prepatients had developed RA and 
when the number of individuals w ith anti-CCP antibodies 
had increased. However, there does not seem to be an 
absolute requirement for SE genes to develop anti-CCP 
antibodies [8]. The ORs for predicting RA were high for 
anti-CCP antibodies and for RFs but comparatively low for 
SE gene carriage. The overriding reason for this difference
is the relatively high frequency among controls of the SE 
gene, which is also evident from the relatively low specifi­
city of SE gene carriage in the prepatients.
A  quite contradictory suggestion is that HLA antigens do 
not predispose to the autoimmune disease per se but 
rather fail to provide protection. Abnormal T-cell regulation 
associated w ith certain HLA haplotypes leads to the loss of 
self-tolerance followed by polyclonal activation of T and B 
cells and the subsequent production of autoantibodies [9]. 
This mechanism could be applicable to autoantibodies 
assessed in this study and would, therefore, explain the 
findings.
In a recent report on the genetic control of RF production 
in a rat model of RA, it was shown that the antibody 
response is controlled by several other genetic regions in 
addition to the defined arthritis loci [10]. The strength of the 
genetic association between HLA-DR4 and RA is reported 
to vary according to disease severity and the population 
studied [11]. The HLA gene locus has been calculated to 
contribute to one-third of the genetic risk for developing RA 
[12,13]. It is, therefore, apparent that other, non-HLA linked 
genes contribute to the risk of RA [14]. Two recent reports 
presented numerous single-nucleotide polymorphisms in 
the peptidyl arginine deiminase enzyme 4, i.e. the enzyme
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converting peptidylarginine to peptidylcitrulline, several of 
which are strongly associated w ith RA [15,16]. Carriers of 
the susceptibility haplotype had antibodies against citrulli- 
nated proteins significantly more often than noncarriers 
[15,16].
The limitation of this study is the sample size, which 
resulted in a relatively low number of individuals in each 
group when the data were stratified for individuals positive 
or negative for a given antibody. Furthermore, we empha­
sise that this is a population-based case-contro l study, 
which makes it possible to establish associations between 
the outcome and the factors studied but precludes calcula­
tion of the probability of being a case, given certain values 
on the analysed factors. In this study, calculations are 
based on the combination of SE and the analysed autoan­
tibodies. This is because anti-CCP antibodies and RFs are 
significantly associated, and consequently prediction of RA 
is only marginally increased when they are considered in 
combination.
Conclusion
This study has demonstrated that the presence of anti-CCP 
antibodies together with SE gene carriage is associated 
with a very high relative risk for future development of RA. 
This strong association w ith future development of RA in 
individuals positive for both SE and anti-CCP antibodies 
poses important questions relating to ethics and health pol­
icy. Thus, we shall need new strategies, both in research 
intended to understand factors that determine whether an 
individual w ith the presently identified risk factors will 
develop RA, and in clinical practice, where we may now 
possess a new means for analysing the risk of future devel­
opment of RA in individuals who w ill have different needs or 
w ishes to acquire such information.
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